Immunogenicity
33
4
8
17
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 33 trials
100.0%
+13.4% vs benchmark
36%
12 trials in Phase 3/4
12%
2 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 17 completed trials
Clinical Trials (33)
Influenza Vaccine Immunogenicity in Repeatedly Vaccinated Older Adults
Influenza Vaccination Strategy for Patients With Hematologic Malignancy
Ex Vivo Immunogenicity Screening of Vaccine Candidate Antigen Combinations in Ethiopian Patients With Leishmaniasis
Immunogenicity of COVID-19 Vaccine on Heterologous Schedule
Real-world Immunogenicity of Anti-IL5/5a Antibody
Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC
A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia
Safety and Immunogenicity of PRO-169 in Patients With Diabetic Macular Edema
Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC
Bioequivalence Clinical Trial of Recombinant Human Follicle-stimulating Hormone JZB30
Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) in Patients With Immune Thrombocytopenia
COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS
Pregnant and Lactating Individuals & Newborns COVID-19 Vaccination Prospective Cohort Study
Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults
A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2
New Generation mRNA Booster Vaccine Against Emerging VOCs
mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs
Protectivity and Safety Following Recombinant Hepatitis B Vaccine
EMaBS TB Vaccine Study
Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) With Pentabio® Vaccine Primed With Recombinant Hepatitis B